1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Omeros Corporation
  6. Summary
    OMER   US6821431029

OMEROS CORPORATION

(OMER)
  Report
Real-time Estimate Cboe BZX  -  10:18 2022-08-10 am EDT
6.865 USD   +10.73%
08/09OMEROS : Q2 Earnings Snapshot
AQ
08/09OMEROS : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/09OMEROS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
5.73(c) 6.83(c) 6.75(c) 6.2(c) 6.915 Last
620 763 999 206 861 162 637 134 218 165 Volume
+6.51% +19.20% -1.17% -8.15% +11.53% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -152 M - -
Net Debt 2022 263 M - -
P/E ratio 2022 -3,06x
Yield 2022 -
Sales 2023 3,12 M - -
Net income 2023 -138 M - -
Net Debt 2023 137 M - -
P/E ratio 2023 -3,39x
Yield 2023 -
Capitalization 389 M 389 M -
EV / Sales 2022 -
EV / Sales 2023 169x
Nbr of Employees 213
Free-Float 96,0%
More Financials
Company
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. Its lead lead MASP-2 inhibitor narsoplimab... 
Sector
Pharmaceuticals
Calendar
08/11Earnings Release
More about the company
Ratings of Omeros Corporation
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about OMEROS CORPORATION
08/09OMEROS : Q2 Earnings Snapshot
AQ
08/09OMEROS : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/09OMEROS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
08/09Omeros Corporation Reports Second Quarter 2022 Financial Results
BU
08/09Omeros Corporation Reports Earnings Results for the Second Quarter and Six Months Ended..
CI
08/04Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
BU
07/29SECTOR UPDATE : Health Care Stocks Remain Lower Ahead of Friday's Close
MT
07/29SECTOR UPDATE : Health Care Stocks Retreat in Friday Trading
MT
07/29Omeros Says FDA Grants Orphan Drug Designation to OMS906 to Treat Blood Cell Disease
MT
07/29FDA Grants Orphan Drug Designation to Omeros' MASP-3 Inhibitor OMS906 for Treatment of ..
BU
07/29Omeros Gets FDA Orphan-Drug Designation for OMS906 in PNH
DJ
06/24OMEROS CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/24OMEROS CORPORATION(NASDAQGM : OMER) dropped from Russell 2500 Index
CI
06/24OMEROS CORPORATION(NASDAQGM : OMER) dropped from Russell 2500 Growth Index
CI
06/24OMEROS CORPORATION(NASDAQGM : OMER) added to Russell Microcap Growth Index
CI
More news
News in other languages on OMEROS CORPORATION
08/09Omeros Corporation annonce ses résultats pour le deuxième trimestre et le semestre clos..
07/29MISE À JOUR SECTORIELLE : Les actions du secteur de la santé restent en baisse avant la cl..
07/29MISE À JOUR SECTORIELLE : Les actions du secteur de la santé reculent dans les échanges de..
07/29Omeros déclare que la FDA accorde la désignation de médicament orphelin à l'OMS906 pour..
06/08Les actions d'Omeros chutent après la rétrogradation de BofA
More news
Analyst Recommendations on OMEROS CORPORATION
More recommendations
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 6,20 $
Average target price 12,17 $
Spread / Average Target 96,2%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Thomas J. Cable Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION-3.58%389
CSL LIMITED2.15%99 702
SAMSUNG BIOLOGICS CO.,LTD.-0.11%49 125
WUXI BIOLOGICS (CAYMAN) INC.-19.50%40 472
BIOGEN INC.-9.31%31 575
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-22.38%22 915